Regional overviews

celebrating 20 years Japan

STATISTICS  
Number of products launched: 9 (2017: 9)#
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:  
0 – 2 years USD0 million
3 – 5 years USD0 million
Number of product recalls: 0 (2017: 0)
Average staff turnover: 12,8% (2017: 20,0%)
Number of work-related fatalities: 0 (2017: 0)
Number of permanent employees:  
Number of permanent employees:  

# The number of product launches has been restated as a result of the refinement of the product launch definition.

 

Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.

Contribution to Group revenue

Revenue - R'million 2018 2017 (CER) % change
Regional Brands 297 172 73
Anaesthetics 1 213 1 204 1
Thrombosis 48 57 (16)
High Potency & Cytotoxics 372 379 (2)
Total 1 930 1 812 7
 
  • The Japanese pharmaceutical sector continues to be negatively impacted by regulated price revisions and was valued at USD80 billion as at 31 December 2017.
Source: December 2017 IMS